Prevalence of Cardiovascular and Cancer Risk Factors Among Rheumatoid Arthritis Patients Prescribed Janus Kinase Inhibitors and Tumor Necrosis Factor Inhibitors: A Cross-Sectional Study.
Jud C JanakRyan D RossBrenna L BradyLiisa PalmerJeffrey T HowardJoshua F BakerPublished in: Arthritis care & research (2024)
In recent years, JAKi and TNFi were used in similar proportions to treat RA among commercially-insured patients at elevated cardiovascular and cancer risk. Because uncontrolled disease, modifiable comorbidities, and treatment with JAKi are associated with these adverse events, future studies evaluating how practice patterns may be affected by the emergence of safety data will be of value.
Keyphrases
- risk factors
- rheumatoid arthritis patients
- disease activity
- rheumatoid arthritis
- papillary thyroid
- systemic lupus erythematosus
- squamous cell carcinoma
- electronic health record
- current status
- big data
- replacement therapy
- combination therapy
- interstitial lung disease
- idiopathic pulmonary fibrosis
- smoking cessation